Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 707 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Preliminary Efficacy Clear all
Terminated Phase 1Phase 2 Interventional Results available

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

NCT05397171
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
AZD8853, Zirconium-89 crefmirlimab berdoxam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Results available

Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors

NCT04205955
View directory record Official record
Conditions
Rectal Carcinoma, Rectosigmoid Carcinoma
Interventions
Best Practice, Dietary Intervention, Message, Quality-of-Life Assessment, Questionnaire Administration
Other · Dietary Supplement
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
225
States / cities
Tucson, Arizona • Costa Mesa, California • Duarte, California + 144 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

NCT02401815
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
CGT9486, Pexidartinib, Sunitinib
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jul 21, 2026, 11:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of SGN1 in Patients With Advanced Solid Tumor

NCT05038150
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
SGN1
Drug
Lead sponsor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 21, 2026, 11:33 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ketamine for OUD and Comorbid Depression (OUDCD)

NCT05051449
View directory record Official record
Conditions
Opioid Use Disorder, Depressive Disorder
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jul 21, 2026, 11:33 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

NCT05388435
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
SKL27969
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Duarte, California • Grand Rapids, Michigan • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jul 21, 2026, 11:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

NCT02221947
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin 1, Placebo
Drug
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE

NCT04643067
View directory record Official record
Conditions
SLE; Drug
Interventions
KPG-818 low dose, KPG-818 mid dose, KPG-818 high dose, Placebo
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Anniston, Alabama • Birmingham, Alabama • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 1 Interventional

A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions

NCT03876106
View directory record Official record
Conditions
EGFR Inhibitor Induced Acneiform Lesions
Interventions
LUT014
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jul 21, 2026, 11:33 PM EDT
Recruiting Not applicable Interventional

Investigation of Surgical Sectioning of the Filum Terminale in Treating Occult Tethered Cord Syndrome Patients

NCT05163899
View directory record Official record
Conditions
Tethered Cord, Tethered Cord Syndrome, Occult Spina Bifida, Spina Bifida Occulta
Interventions
Release of filum terminale
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
2 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Results available

Preliminary Study of Safety and Efficacy of Policosanol

NCT00312923
View directory record Official record
Conditions
Dyslipidemia, HIV Infections
Interventions
Policosanol, Placebo
Drug · Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Jul 21, 2026, 11:33 PM EDT
Not listed Not applicable Interventional

Direct Application of Integra Bilayer Matrices on Bare Calvarium Without Preliminary Burring

NCT05311124
View directory record Official record
Conditions
Wound Care, Pressure Ulcer, Venous Ulcer, Surgical Wound, Trauma Wounds, Draining Wound
Interventions
Integra Dermal Regeneration template (IDRT)
Device
Lead sponsor
Joshua Choo
Other
Eligibility
55 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 1 Interventional

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

NCT01576666
View directory record Official record
Conditions
Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions
LDE225, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 21, 2026, 11:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

NCT05984927
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
NG101 AAV gene therapy
Genetic
Lead sponsor
Elisigen, Inc.
Industry
Eligibility
50 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Cincinnati, Ohio • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 2 Interventional

Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion

NCT00996073
View directory record Official record
Conditions
Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis
Interventions
Lumbar Interbody Fusion with Autograft, Lumbar Interbody Fusion with NeoFuse
Biological
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
5
States / cities
Santa Monica, California • Greenwood Village, Colorado • Loveland, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Jul 21, 2026, 11:33 PM EDT
Active, not recruiting Phase 1 Interventional

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

NCT05184569
View directory record Official record
Conditions
Semantic Dementia
Interventions
Verdiperstat
Drug
Lead sponsor
Peter Ljubenkov, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 11:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

NCT06459973
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
intravenous (IV) infusion
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 21, 2026, 11:33 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

NCT01021956
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
STAKEL
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • West Columbia, South Carolina • Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

NCT02588105
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
AZD0156, Olaparib, irinotecan, Fluorouracil, Folinic Acid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2022 · Synced Jul 21, 2026, 11:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT06388707
View directory record Official record
Conditions
Drug Resistant Epilepsy, Epilepsy, Seizures, Focal, Seizure, Seizure Disorder
Interventions
NaviFUS System
Device
Lead sponsor
NaviFUS Corporation
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Palo Alto, California • Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Results available

Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

NCT02217332
View directory record Official record
Conditions
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Interventions
dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Boca Raton, Florida • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Results available

Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance

NCT01532518
View directory record Official record
Conditions
Colic
Interventions
Nepadutant
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
Up to 6 Months
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 1 Interventional

A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT03787498
View directory record Official record
Conditions
Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
Interventions
PLX2853
Drug
Lead sponsor
Opna Bio LLC
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Jul 21, 2026, 11:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

NCT00312663
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Falciparum Malaria Protein 11 with AS01B adjuvant.
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2018 · Synced Jul 21, 2026, 11:33 PM EDT